Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ESHAP regimen

Known as: Etoposide-Solumedrol-High Dose Ara-C, Platinol Regimen 
A regimen consisting of etoposide, methylprednisolone, high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin's and non… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
ABSTRACT Background: Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin… Expand
2010
2010
BACKGROUND High-dose chemotherapy (HDT) followed by autologous stem-cell transplantation (ASCT) is considered the gold standard… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
Highly Cited
2008
Highly Cited
2008
AIM To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell… Expand
  • table 1
  • table 2
  • figure 2
  • figure 3
  • table 3
Highly Cited
2008
Highly Cited
2008
The findings of this study suggest that combined therapy wih rituximab, etoposide, cytarabine, cisplatinum and methylprednisolone… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2008
2008
We describe the rare case of a 53-year-old woman with systemic involvement of Langerhans cell sarcoma (LCS) who had undergone… Expand
2007
2007
BACKGROUND We evaluated the efficacy and safety of adding rituximab to nonanthracycline ESHAP (etoposide/methylprednisolone… Expand
2006
2006
Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease 
2005
2005
The outcome of patients (pts) with PTCL receiving conventional therapy is dismal. Because of this, there is an increasing… Expand
2002
2002
The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
1999
1999
The purpose was study the feasibility of ESHAP + G-CSF for peripheral blood hematopoietic progenitor cell (PBPC) mobilisation in… Expand